AUTHORS
Pavan Reddy, PhD, Stefanie Meyer2, Hanzhi Zhang3, Mulin Fang4, Steven Frey5, Yu Shi6, Xiuling Li7, David Sermer, MD8, Denise Brennan, BS9, Margaret Wey, PhD10, Marcio Andrade-Campos, MD, PhD11, Corinne Cayatte, PhD12, Mariano Severgnini13, Sameh Gaballa, MD14, Koji Izutsu, MD, PhD15, Sumana Devata, MD16, Ibrahim Aldoss, MD17, Bela Patel, MD FRCPath18, Prof. Dr. Max Topp, MD19, Nicholas Durham, PhD20
AFFILIATIONS
1 Astrazeneca, Hematology Oncology R&D, Waltham, Massachusetts, United States
2 Astrazeneca, Hematology Oncology R&D, Waltham, Massachusetts, United States
3 Astrazeneca, Biologics Engineering R&D, Gaithersburg, United States
4 Astrazeneca, Biopharmaceutical Development, Gaithersburg, Maryland, United States
5 Astrazeneca, Biologics Engineering R&D, Gaithersburg, United States
6 Astrazeneca, Biopharmaceutical Development, Gaithersburg, Maryland, United States
7 Astrazeneca, Biologics Engineering R&D, Gaithersburg, United States
8 Astrazeneca, Hematology Oncology R&D, New York, New York, United States
9 Astrazeneca, Hematology Oncology R&D, Waltham, Massachusetts, United States
10 Astrazeneca, Hematology Oncology R&D, Waltham, Massachusetts, United States
11 Astrazeneca, Hematology Oncology R&D, Barcelona, Spain
12 Astrazeneca, Early Oncology R&D, Gaithersburg, Maryland, United States
13 Astrazeneca, Hematology Oncology R&D, Waltham, Massachusetts, United States
14 H. Lee Moffitt Cancer Center and Research Institute, Tampa, United States
15 National Cancer Center Hospital, Tokyo, Japan, Tokyo, Japan
16 Medical College of Wisconsin,, Milwaukee, Wisconsin, United States
17 City of Hope Comprehensive Cancer Center, Duarte, California, United States
18 Barts Cancer Institute, Queen Mary University of London, London, United Kingdom
19 Universitätsklinikum Würzburg, Würzburg, Germany
20 Astrazeneca, Hematology Oncology R&D, Gaithersburg, Maryland, United States
ABSTRACT
Background: Surovatamig is a fully human IgG4 CD19×CD3 bispecific T-cell engager (TCE) that has shown clinical activity with a manageable safety profile in several of B-cell malignancies. CD19-directed TCEs and CAR-T therapies have transformed outcomes in B-cell malignancies, yet antigen modulation, including CD19 alternative splicing, point mutations, and surface downregulation, can lead to resistance and disease progression. Systematic comparison of CD19-binding epitopes across major therapeutic modalities may inform rational therapy sequencing and improve understanding of differential susceptibility to antigen escape; to our knowledge, such analyses have not been reported. We characterized the CD19 epitope targeted by surovatamig relative to blinatumomab (B43) and FMC63, the mouse-derived scFv used in CAR-T therapies, and correlated epitope differences with clinical activity following prior CD19-directed therapy in two surovatamig clinical studies.
Methods: For fine epitope mapping, hydrogen–deuterium exchange mass spectrometry (HDX-MS) was performed on surovatamig VHH and B43 scFv, each in complex with CD19 antigen. Structural modeling of the surovatamig–CD19 and B43–CD19 complexes was performed based on HDX-MS–determined binding hot spots. Competitive binding was assessed by flow cytometry on CD19-expressing Raji B-NHL cells preincubated with unlabeled B43, FMC63, or surovatamig at 1–500 µg/mL, followed by detection with PE-labeled surovatamig; unlabeled surovatamig served as a positive control for competition. Clinical activity of surovatamig after prior CD19-directed therapy was evaluated in the two ongoing phase 1 studies in relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL) (NCT04594642) and R/R B-cell acute lymphoblastic leukemia (B-ALL) (NCT06137118). For both studies, patients were required to have documented CD19 positivity after the last CD19-targeted therapy or be CD19-positive at study entry.
Results: In the HDX-MS assay, surovatamig protected two distinct CD19 regions—S1 (aa 49–60, exon 2) and S2 (aa 260–269, exons 5/6)—with contacts driven primarily by VHH CDR3 and CDR2. These sites did not overlap with the three B43-protected regions—B1 (aa 103–105, exon 3), B2 (aa 155–162, exon 4), and B3 (aa 208–217, exon 5)—or the previously published FMC63 epitopes F1 (aa 170–173, exon 4) and F2 (aa 212–217, exon 5) (Teplyakov A et al., Proteins 2018). Comparative epitope mapping revealed partial overlap between the B43 (B3: aa 208–217, exon 5) and FMC63 (F2: aa 212–217, exon 5) contact regions, indicating a shared binding determinant on CD19. In contrast, surovatamig engages two entirely distinct sites with no sequence overlap with either B43 or FMC63.
In competitive binding assays, consistent with the distinct epitope identified by HDX-MS, Raji cells preincubated with FMC63 or B43 (1–500 µg/mL) showed no reduction in subsequent PE-surovatamig binding, functionally confirming that surovatamig recognizes a non-overlapping CD19 epitope. Unlabeled surovatamig fully blocked PE-surovatamig binding (>95% MFI reduction), serving as a positive control for assay sensitivity.
In two phase 1 studies of patients with R/R B-cell malignancies, surovatamig demonstrated clinical activity in patients previously treated with CD19-directed therapy (data cutoff: May 2026). The complete remission (CR) rate in patients following prior CD19-directed CAR-T therapies was 41% (16/39) in R/R diffuse large B-cell lymphoma (DLBCL) at target doses (TD) ≥7.2 mg and 67% (4/6) in R/R follicular lymphoma at TD ≥2.4 mg. In the phase 1/2 SYRUS study in R/R B-ALL, among efficacy-evaluable patients who had previously received blinatumomab, 46% (26/57) achieved CR or CR with partial hematologic recovery (CRh) at TD ≥2.4 mg; among efficacy-evaluable patients who had previously received CAR-T therapies, 49% (19/39) achieved CR or CRh. Responders to surovatamig included patients who were refractory to prior CD19-directed CAR-T therapies.
Conclusions: Surovatamig binds a CD19 epitope that is distinct from those targeted by B43 and FMC63. The non-overlapping epitope may contribute to retained activity against disease progressing after other CD19-directed therapies. Further mapping of CD19 antigen loss by mutation remains important to fully understand susceptibility to escape. Together, these data provide a mechanistic rationale for enrolling patients with prior CD19-directed therapies into surovatamig trials and inform rational combinations and sequencing.
DISCLOSURES
Pavan Reddy, PhD: Astrazeneca - Current Employment